➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Merck
McKesson
McKinsey
Mallinckrodt

Last Updated: July 6, 2020

DrugPatentWatch Database Preview

Salmeterol xinafoate - Generic Drug Details

» See Plans and Pricing

« Back to Dashboard

What are the generic sources for salmeterol xinafoate and what is the scope of patent protection?

Salmeterol xinafoate is the generic ingredient in one branded drug marketed by Glaxosmithkline and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

There are nineteen drug master file entries for salmeterol xinafoate. One supplier is listed for this compound.

Recent Clinical Trials for salmeterol xinafoate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Parc de Salut MarPhase 1
BECRO Ltd.Phase 1
Respirent Pharmaceuticals Co Ltd.Phase 1

See all salmeterol xinafoate clinical trials

Pharmacology for salmeterol xinafoate
Medical Subject Heading (MeSH) Categories for salmeterol xinafoate

US Patents and Regulatory Information for salmeterol xinafoate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline SEREVENT salmeterol xinafoate POWDER;INHALATION 020692-001 Sep 19, 1997 RX Yes Yes   Start Trial   Start Trial   Start Trial
Glaxosmithkline SEREVENT salmeterol xinafoate AEROSOL, METERED;INHALATION 020236-001 Feb 4, 1994 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for salmeterol xinafoate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline SEREVENT salmeterol xinafoate POWDER;INHALATION 020692-001 Sep 19, 1997   Start Trial   Start Trial
Glaxosmithkline SEREVENT salmeterol xinafoate POWDER;INHALATION 020692-001 Sep 19, 1997   Start Trial   Start Trial
Glaxosmithkline SEREVENT salmeterol xinafoate AEROSOL, METERED;INHALATION 020236-001 Feb 4, 1994   Start Trial   Start Trial
Glaxosmithkline SEREVENT salmeterol xinafoate POWDER;INHALATION 020692-001 Sep 19, 1997   Start Trial   Start Trial
Glaxosmithkline SEREVENT salmeterol xinafoate POWDER;INHALATION 020692-001 Sep 19, 1997   Start Trial   Start Trial
Glaxosmithkline SEREVENT salmeterol xinafoate POWDER;INHALATION 020692-001 Sep 19, 1997   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Merck
McKesson
McKinsey
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.